References
- O’SullivanCCRuddyKJManagement of potential long-term toxicities in breast cancer patientsCurr Breast Cancer Rep20168418319228503254
- van der BurgBde GrootRPIsbrückerLKruijerWde LaatSWDirect stimulation by estrogen of growth factor signal transduction pathways in human breast cancer cellsJ Steroid Biochem Mol Biol1992431–31111151525051
- ClarkeBLKhoslaSAndrogens and boneSteroids200974329630518992761
- HadjiPAaproMSBodyJJManagement of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGJ Bone Oncol2017711228413771
- StrattonJHuXSoulosPRBone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitorsJ Oncol Pract2017135e505e51528267392
- SmithIYardleyDBurrisHComparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized Phase III femara versus anastrozole clinical evaluation (FACE) trialJ Clin Oncol201735101041104828113032
- EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
- McClungMRLewieckiEMCohenSBAMG 162 Bone Loss Study GroupDenosumab in postmenopausal women with low bone mineral densityN Engl J Med2006354882183116495394
- SilvaIBrancoJCDenosumab: recent update in postmenopausal osteoporosisActa Reumatol Port201237430231324126422
- FerrariSAdachiJDLippunerKFurther reductions in non-vertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 yearsOsteoporos Int201526122763277126068295
- KamimuraMNakamuraYIkegamiSSignificant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive casesOsteoporos Int201728255956627650642
- GnantMPfeilerGDubskyPCAustrian Breast and Colorectal Cancer Study GroupAdjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialLancet2015386999243344326040499
- ToulisKIliadouPMandanasSCalcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single dose of denosumab: a pilot studyHormones (Athens)201615456056228222416
- SoenSFukunagaMSugimotoTNew diagnostic criteria and guidelines on osteoporosis. Diagnostic criteria for primary osteoporosis: year 2012 revisionClin Calcium2014241323329 Japanese24576928
- PacificiRBrownCPuscheckEEffect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cellsProc Natl Acad Sci U S A19918812513451382052592
- BundredNJCampbellIDDavidsonNEffective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozoleCancer200811251001101018205185
- NakamuraYSuzukiTKamimuraMVitamin D and calcium are required at the time of denosumab administration during osteoporosis treatmentBone Res201751702129021920
- NakamuraTMatsumotoTSugimotoTShirakiMDose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosisOsteoporos Int20122331131114021927920